4.8 Article

Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis

Journal

LANCET
Volume 378, Issue 9799, Pages 1306-1315

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(11)60873-8

Keywords

-

Funding

  1. Bailly Thomas charity
  2. Medical Research Council
  3. NIHR
  4. Servier
  5. UK Medical Research Council
  6. UK Economic and Social Research Council
  7. National Institute for Health Research
  8. Stanley Medical Research Institute
  9. European Research Council [260559 IMMA]
  10. National Institute for Health Research [NF-SI-0510-10102] Funding Source: researchfish

Ask authors/readers for more resources

Background Conventional meta-analyses have shown inconsistent results for efficacy of pharmacological treatments for acute mania. We did a multiple-treatments meta-analysis, which accounted for both direct and indirect comparisons, to assess the effects of all antimanic drugs. Methods We systematically reviewed 68 randomised controlled trials (16 073 participants) from Jan 1, 1980, to Nov 25, 2010, which compared any of the following pharmacological drugs at therapeutic dose range for the treatment of acute mania in adults: aripiprazole, asenapine, carbamazepine, valproate, gabapentin, haloperidol, lamotrigine, lithium, olanzapine, quetiapine, risperidone, topiramate, and ziprasidone. The main outcomes were the mean change on mania rating scales and the number of patients who dropped out of the allocated treatment at 3 weeks. Analysis was done by intention to treat. Findings Haloperidol (standardised mean difference [SMD] -0.56 [95% CI -0.69 to -0.43]), risperidone (-0.50 [-0.63 to -0.38]), olanzapine (-0.43 [-0.54 to -0.32], lithium (-0.37 [-0.63 to -0.11]), quetiapine (-0.37 [-0.51 to -0.23]), aripiprazole (-0.37 [-0.51 to -0.23]), carbamazepine (-0.36 [-0.60 to -0.11], asenapine (-0.30 [-0.53 to -0.07]), valproate (-0.20 [-0.37 to -0.04]), and ziprasidone (-0.20 [-0.37 to -0.03]) were significantly more effective than placebo, whereas gabapentin, lamotrigine, and topiramate were not. Haloperidol had the highest number of significant differences and was significantly more effective than lithium (SMD -0.19 [95% CI -0.36 to -0.01]), quetiapine (-0.19 [-0.37 to 0.01]), aripiprazole (-0.19 [-0.36 to -0.02]), carbamazepine (-0.20 [-0.36 to -0.01]), asenapine (-0.26 [-0.52 to 0.01]), valproate (-0.36 [-0.56 to -0.15]), ziprasidone (-0.36 [-0.56 to -0.15]), lamotrigine (-0.48 [-0.77 to -0.19]), topiramate (-0.63 [-0.84 to -0.43]), and gabapentin (-0.88 [-1.40 to -0.36]). Risperidone and olanzapine had a very similar profile of comparative efficacy, being more effective than valproate, ziprasidone, lamotrigine, topiramate, and gabapentin. Olanzapine, risperidone, and quetiapine led to significantly fewer discontinuations than did lithium, lamotrigine, placebo, topiramate, and gabapentin. Interpretation Overall, antipsychotic drugs were significantly more effective than mood stabilisers. Risperidone, olanzapine, and haloperidol should be considered as among the best of the available options for the treatment of manic episodes. These results should be considered in the development of clinical practice guidelines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available